US pharmaceutical Company, Aerie Pharmaceuticals, Inc. is to establish its first manufacturing plant in Athlone.
Aerie is a clinical stage pharmaceutical company focused on the discovery, development and commercialisation of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Aerie’s new facility in Athlone is expected to commercially supply global markets with Aerie’s current product candidates, Rhopressa® and RoclatanTM, in 2020. If approved these products have the potential to be classified as the first new mechanisms of action for the treatment of patient with glaucoma in 20 years.
This state of the art facility will include end to end operations – compounding, sterile filling, and packaging with all necessary support capabilities.